21 September 2020
The US Food and Drug Administration - Center for Veterinary Medicine (FDA-CVM) has concluded that all technical sections for the STELFONTA (tigilanol tiglate) application for marketing authorisation are complete. The final stage of administrative review has commenced, with formal registration as a veterinary pharmaceutical expected mid-November 2020 pending approval.
Qbiotics, page-124
-
- There are more pages in this discussion • 1,116 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)